Search research articles
Contact Us
Filters
Showing results (241-250 of 289) with videos related to
Page
of 29
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Health Beliefs and Adherence to Lung Cancer Screening in a Diverse Safety-Net Population
Sheena Bhalla, Heidi A Hamann, Tanushree Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Translational Oncology
|
June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
Vatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
The Oncologist
|
May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Clinical Lung Cancer
|
August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Oncoimmunology
|
June 15, 2018
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
Osama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, et al.
Clinical Lung Cancer
|
May 27, 2022
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population
Harris Majeed, Hong Zhu, Sarah A Williams, et al.
Journal for Immunotherapy of Cancer
|
October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer
Prithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 26, 2024
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 289) with videos related to
Sort By:
Page
of 29
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Health Beliefs and Adherence to Lung Cancer Screening in a Diverse Safety-Net Population
Sheena Bhalla, Heidi A Hamann, Tanushree Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Translational Oncology
|
June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
Vatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
The Oncologist
|
May 14, 2020
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
Mitchell S von Itzstein, Shaheen Khan, Vinita Popat, et al.
Clinical Lung Cancer
|
August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Oncoimmunology
|
June 15, 2018
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
Osama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, et al.
Clinical Lung Cancer
|
May 27, 2022
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population
Harris Majeed, Hong Zhu, Sarah A Williams, et al.
Journal for Immunotherapy of Cancer
|
October 28, 2025
Genetic haplotypes in <i>VWA8, OSBPL6,</i> and <i>ADAMTS9-AS2</i> are associated with immune-related adverse effects in ICI-treated patients with cancer
Prithvi Raj, Jialiang Liu, Chengsong Zhu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 26, 2024
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Page
of 29